Susmitha Apuri. Neoadjuvant and Adjuvant Therapies for Breast Cancer. South Med J. 2017;110(10):638-642. doi: 10.14423/SMJ.0000000000000703..
DOI: 10.14423/SMJ.0000000000000703

Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030..
DOI: 10.1016/j.ccr.2007.08.030

Fabi A., Di Benedetto A., Metro G., Perracchio L., Nisticò C., Di Filippo F., et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clinical Cancer Research. 2011;17(7):205520-64. doi: 10.1158/1078-0432.CCR-10-1920..
DOI: 10.1158/1078-0432.CCR-10-1920

von Minckwitz G., Procter M., de Azambuja E., Zardavas D., Benyunes M., et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131. doi: 10.1056/NEJMoa1703643..
DOI: 10.1056/NEJMoa1703643

Untch M., Fasching P.A., Konecny G.E., Hasmüller S., Lebeau A., Kreienberg R., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-3357. doi: 10.1200/JCO.2010.31.4930..
DOI: 10.1200/JCO.2010.31.4930

de Azambuja E., Holmes A.P., Piccart-Gebhart M., Holmes E., Di Cosimo S., Swaby R.F., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137-1146. doi: 10.1016/S1470-2045(14)70320-1..
DOI: 10.1016/S1470-2045(14)70320-1

Cardoso F., Kyriakides S., Ohno S., PenaultLlorca F., Poortmans P., Rubio I.T., Zackrisson S., Senkus E. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019. pii: mdz189. doi: 10.1093/annonc/mdz189..
DOI: 10.1093/annonc/mdz189

Inno A., Barni S., Ghidini A., Zaniboni A., Petrelli F. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;173(2):247-254. doi: 10.1007/s10549-018-5001-x..
DOI: 10.1007/s10549-018-5001-x

Zardavas D., Fouad T.M., Piccart M. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. Breast (Edinburgh, Scotland). 2015;24(Suppl 2):143-148. doi: 10.1016/j.breast.2015.07.034..
DOI: 10.1016/j.breast.2015.07.034

Burris H.A. 3rd, Rugo H.S., Vukelja S.J., Vogel C.L., Borson R.A., Limentani S., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398-405. doi: 10.1200/JCO.2010.29.5865..
DOI: 10.1200/JCO.2010.29.5865

Peddi P.F., Hurvitz S.A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013;9(3):319-326. doi: 10.2217/fon.13.7..
DOI: 10.2217/fon.13.7

Krop I.E., Kim S.B., González-Martín A., LoRusso P.M., Ferrero J.M., Smitt M., Yu R., et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689-699. doi: 10.1016/S1470-2045(14)70178-0..
DOI: 10.1016/S1470-2045(14)70178-0

Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791. doi: 10.1056/NEJMoa1209124..
DOI: 10.1056/NEJMoa1209124

Penault-Llorca F., Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nature reviews. Clinical oncology. 2016;13(8):487–503. doi: 10.1038/nrclinonc.2016.1..
DOI: 10.1038/nrclinonc.2016.1

Prowell T.M., Beaver J.A., Pazdur R. Residual Disease after Neoadjuvant Therapy – Developing Drugs for High-Risk Early Breast Cancer. N Engl J Med. 2019;380(7):612-615. doi: 10.1056/NEJMp1900079..
DOI: 10.1056/NEJMp1900079

Pernas S., Barroso-Sousa R., Tolaney S.M. Optimal treatment of early stage HER2-positive breast cancer. Cancer. 2018;124(23):4455-4466. doi: 10.1002/cncr.31657..
DOI: 10.1002/cncr.31657

Wuerstlein R., Harbeck N. Neoadjuvant Therapy for HER2-positive Breast Cancer. Reviews on recent clinical trials. 2017;12(2):81–92. doi: 10.2174/1574887112666170202165049..
DOI: 10.2174/1574887112666170202165049

Hanusch C., Schneeweiss A., Loibl S., Untch M., Paepke S., Kümmel S., et al. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving TaxaneAnthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res. 2015;21(13):2924-2931. doi: 10.1158/1078-0432.CCR-14-2774..
DOI: 10.1158/1078-0432.CCR-14-2774

Kalous O., Conklin D., Desai A.J., et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012;11(9):1978-1987. doi: 10.1158/1535-7163.MCT-11-0730..
DOI: 10.1158/1535-7163.MCT-11-0730

Martin M., Holmes F.A., et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2017;18(12)1688–1700. doi: 10.1016/S1470-2045(17)30717-9..
DOI: 10.1016/S1470-2045(17)30717-9

Piccart-Gebhart M., Holmes E., Baselga J., de Azambuja E., Dueck A.C., Viale G., et al. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. 2016;34(10):1034-1042. doi: 10.1200/JCO.2015.62.1797..
DOI: 10.1200/JCO.2015.62.1797

Castaneda S.A., Strasser J. Updates in the Treatment of Breast Cancer with Radiotherapy. Surg Oncol Clin N Am. 2017;26(3):371-382. doi: 10.1016/j.soc.2017.01.013.
DOI: 10.1016/j.soc.2017.01.013

Shah C., Tendulkar R., Smile T., et al. Adjuvant Radiotherapy in Early-Stage Breast Cancer: Evidence-Based Options. Ann Surg Oncol. 2016;23:3880. doi: 10.1245/s10434-016-5503-x..
DOI: 10.1245/s10434-016-5503-x

I van Hellemond I.E.G, Geurts S.M.E., TjanHeijnen V.C.G. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. Curr Treat Options Oncol. 2018;19(5):26. doi: 10.1007/s11864-018-0541-1..
DOI: 10.1007/s11864-018-0541-1

Gourgou-Bourgade S., Cameron D., Poortmans P., Asselain B., Azria D., Cardoso F., et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015;26(5):873-879. doi: 10.1093/annonc/mdv106..
DOI: 10.1093/annonc/mdv106

Hudis C.A., Barlow W.E., Costantino J.P., Gray R.J., Pritchard K.I., Chapman J.A., et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127-2132. doi: 10.1200/JCO.2006.10.3523..
DOI: 10.1200/JCO.2006.10.3523

Krop I.E., Suter T.M., Dang C.T., Dirix L., Romieu G., Zamagni C., et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive earlystage breast cancer. J Clin Oncol. 2015;33(10):1136-1142. doi: 10.1200/JCO.2014.58.7782..
DOI: 10.1200/JCO.2014.58.7782

von Minckwitz G., Huang C.S., Mano M.S., Loibl S., Mamounas E.P., Untch M. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628. doi: 10.1056/NEJMoa1814017..
DOI: 10.1056/NEJMoa1814017